{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:08:52Z","timestamp":1765994932641,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2012_A103, 2015_A228"],"award-info":[{"award-number":["2012_A103, 2015_A228"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271-TRR 205, 413635475"],"award-info":[{"award-number":["314061271-TRR 205, 413635475"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Glucocorticoid excess exhibits multiple detrimental effects by its catabolic properties. Metformin was recently suggested to protect from adverse metabolic side-effects of glucocorticoid treatment. Whether metformin is beneficial in patients with endogenous glucocorticoid excess has not been clarified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the phenotype in patients with endogenous Cushing\u2019s syndrome (CS) treated with metformin at the time of diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>As part of the German Cushing\u2019s Registry we selected from our prospective cohort of 96 patients all 10 patients who had been on pre-existing metformin treatment at time of diagnosis (CS-MET). These 10 patients were matched for age, sex and BMI with 16 patients without metformin treatment (CS-NOMET). All patients had florid CS at time of diagnosis. We analyzed body composition, metabolic parameters, bone mineral density and bone remodeling markers, muscle function and quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As expected, diabetes was more prevalent in the CS-MET group, and HbA1c was higher. In terms of comorbidities and the degree of hypercortisolism, the two groups were comparable. We did not observe differences in terms of muscle function or body composition. In contrast, bone mineral density in metformin-treated patients was superior to the CS-NOMET group at time of diagnosis (median T-Score -0.8 <jats:italic>versus<\/jats:italic> -1.4, <jats:italic>p<\/jats:italic> = 0.030). CS-MET patients showed decreased \u03b2-CTX levels at baseline (<jats:italic>p<\/jats:italic> = 0.041), suggesting reduced bone resorption under metformin treatment during glucocorticoid excess.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This retrospective cohort study supports potential protective effects of metformin in patients with endogenous glucocorticoid excess, in particular on bone metabolism.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.765067","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:20:08Z","timestamp":1635315608000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Frederick","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"German","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Zopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"O\u00dfwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Schmidmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s Syndrome: State of the Art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.8.5896","article-title":"Persistence of Increased Cardiovascular Risk in Patients With Cushing\u2019s Disease After Five Years of Successful Cure","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1945","article-title":"Long-Term Cognitive Impairments and Attentional Deficits in Patients With Cushing\u2019s Disease and Cortisol-Producing Adrenal Adenoma in Remission","volume":"97","author":"Ragnarsson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0464","article-title":"High Mortality Within 90 Days of Diagnosis in Patients With Cushing\u2019s Syndrome: Results From the ERCUSYN Registry","volume":"181","author":"Valassi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30021-8","article-title":"Metformin to Reduce Metabolic Complications and Inflammation in Patients on Systemic Glucocorticoid Therapy: A Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Trial","volume":"8","author":"Pernicova","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e015154","DOI":"10.1161\/JAHA.119.015154","article-title":"Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats","volume":"9","author":"Li","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12020-021-02687-0","article-title":"Metformin in Non-Diabetic Patients With Metabolic Syndrome and Diastolic Dysfunction: The MET-DIME Randomized Trial","volume":"72","author":"Ladeiras-Lopes","year":"2021","journal-title":"Endocrine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00878-7","article-title":"The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients With Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"17","author":"Abdallah","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/JME-19-0083","article-title":"The Role of an Anti-Diabetic Drug Metformin in the Treatment of Endocrine Tumors","volume":"63","author":"Thakur","year":"2019","journal-title":"J Mol Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2013Mode of Action and Clinical Implications for Diabetes and Cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/srep20441","article-title":"Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology","volume":"6","author":"Hart","year":"2016","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0689","article-title":"Persistence of Myopathy in Cushing\u2019s Syndrome: Evaluation of the German Cushing\u2019s Registry","volume":"176","author":"Berr","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02204","article-title":"Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy","volume":"104","author":"Osswald","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4033","article-title":"The Effect of Biochemical Remission on Bone Metabolism in Cushing\u2019s Syndrome: A 2-Year Follow-Up Study","volume":"35","author":"Braun","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00766","article-title":"Toward a Diagnostic Score in Cushing\u2019s Syndrome","volume":"10","author":"Braun","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","first-page":"499","article-title":"Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) as a Marker of Bone Resorption","volume":"52","author":"Halleen","year":"2006","journal-title":"Clin Lab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2012-0531","article-title":"IDS Isys Automated Intact Procollagen-1-N-Terminus Pro-Peptide Assay: Method Evaluation and Reference Intervals in Adults and Children","volume":"51","author":"Morovat","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","article-title":"Clinical Usefulness of Bone Turnover Marker Concentrations in Osteoporosis","volume":"467","author":"Morris","year":"2017","journal-title":"Clin Chim Acta"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e4490","DOI":"10.1210\/clinem\/dgaa625","article-title":"Persisting Muscle Dysfunction in Cushing\u2019s Syndrome Despite Biochemical Remission","volume":"105","author":"Vogel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","first-page":"69","article-title":"Grip and Pinch Strength: Normative Data for Adults","volume":"66","author":"Mathiowetz","year":"1985","journal-title":"Arch Phys Med Rehabil"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of Health-Related Quality of Life in Patients With Cushing\u2019s Syndrome With a New Questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0572","article-title":"Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients With Type 2 Diabetes","volume":"95","author":"Zinman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090732","article-title":"Effect of Metformin on Bone Marrow Progenitor Cell Differentiation: In Vivo and In Vitro Studies","volume":"25","author":"Molinuevo","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.07.033","article-title":"Metformin Prevents Anti-Osteogenic In Vivo and Ex Vivo Effects of Rosiglitazone in Rats","volume":"668","author":"Sedlinsky","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7626215","article-title":"Effect of the Abnormal Expression of BMP-4 in the Blood of Diabetic Patients on the Osteogenic Differentiation Potential of Alveolar Bmscs and the Rescue Effect of Metformin: A Bioinformatics-Based Study","volume":"2020","author":"Liang","year":"2020","journal-title":"BioMed Res Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.934297","article-title":"Effect of Antidiabetic Treatment on Bone","volume":"68","author":"Jackuliak","year":"2019","journal-title":"Physiol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e000999","DOI":"10.1136\/bmjdrc-2019-000999","article-title":"Association Between non-Alcoholic Fatty Liver Disease-Associated Hepatic Fibrosis and Bone Mineral Density in Postmenopausal Women With Type 2 Diabetes or Impaired Glucose Regulation","volume":"8","author":"Zhu","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00926","article-title":"Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes","volume":"10","author":"Wang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.3390\/ijerph17103695","article-title":"Optimizing the Interaction of Exercise Volume and Metformin to Induce a Clinically Significant Reduction in Metabolic Syndrome Severity: A Randomised Trial","volume":"17","author":"Ramos","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e13039","DOI":"10.1111\/acel.13039","article-title":"Metformin Blunts Muscle Hypertrophy in Response to Progressive Resistance Exercise Training in Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial: The MASTERS Trial","volume":"18","author":"Walton","year":"2019","journal-title":"Aging Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e14307","DOI":"10.14814\/phy2.14307","article-title":"Metformin Does Not Compromise Energy Status in Human Skeletal Muscle at Rest or During Acute Exercise: A Randomised, Crossover Trial","volume":"7","author":"Kristensen","year":"2019","journal-title":"Physiol Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00517","article-title":"Metformin Enhances Antidepressant\/Antipsychotic Combination Therapy of Schizophrenia With Comorbid Depression in a Murine Model","volume":"14","author":"Zhou","year":"2020","journal-title":"Front Neurosci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.6.46","article-title":"Metformin Corrects Abnormal Circadian Rhythm and Kir4.1 Channels in Diabetes","volume":"61","author":"Alex","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.8.2420","article-title":"The Antidiabetic Drug Metformin Activates the AMP-Activated Protein Kinase Cascade via an Adenine Nucleotide-Independent Mechanism","volume":"51","author":"Hawley","year":"2002","journal-title":"Diabetes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-094144","article-title":"AMP-Activated Protein Kinase Mediates Glucocorticoid-Induced Metabolic Changes: A Novel Mechanism in Cushing\u2019s Syndrome","volume":"22","author":"Christ-Crain","year":"2008","journal-title":"FASEB J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1297","article-title":"Changes in Adenosine 5\u2019-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing\u2019s Syndrome","volume":"93","author":"Kola","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104588","article-title":"The Influence of Metformin on IGF-1 Levels in Humans: A Systematic Review and Meta-Analysis","volume":"151","author":"Yang","year":"2020","journal-title":"Pharmacol Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/465282","article-title":"Metformin Stimulates FGF21 Expression in Primary Hepatocytes","volume":"2012","author":"Nygaard","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0391","article-title":"The Effects of Metformin on Fibroblast Growth Factor 19, 21 and Fibroblast Growth Factor Receptor 1 in High-Fat Diet and Streptozotocin Induced Diabetic Rats","volume":"64","author":"Wang","year":"2017","journal-title":"Endocr J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5813030","article-title":"Metformin Prevents Fatty Liver and Improves Balance of White\/Brown Adipose in an Obesity Mouse Model by Inducing FGF21","volume":"2016","author":"Kim","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02373-7","article-title":"Differential Effects of Metformin on Reductive Activity and Energy Production in Pituitary Tumor Cells Compared to Myogenic Precursors","volume":"69","author":"Tulipano","year":"2020","journal-title":"Endocrine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mce.2018.07.007","article-title":"Metformin Suppresses Growth and Adrenocorticotrophic Hormone Secretion in Mouse Pituitary Corticotroph Tumor Att20cells","volume":"478","author":"Jin","year":"2018","journal-title":"Mol Cell Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.765067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:20:13Z","timestamp":1635315613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.765067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":42,"alternative-id":["10.3389\/fendo.2021.765067"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.765067","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"article-number":"765067"}}